Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

Inflamm Bowel Dis. 2007 Aug;13(8):1024-30. doi: 10.1002/ibd.20169.


Therapy for the inflammatory bowel diseases increasingly includes the use of immune-modifying and biologic therapies. Recently, in young patients with IBD, an association has been noted between the use of infliximab along with concomitant purine analogues and the development of hepatosplenic T-cell lymphoma (HSTCL)-a rare and all but incurable form of non-Hodgkin's lymphoma. This report briefly reviews the issue of lymphoma and IBD therapy. Additionally, a description of HSTCL and a summary of the known cases of this apparent therapeutic complication are presented. Clinical options in light of this new information are explored.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Monoclonal / adverse effects*
  • Child
  • Crohn Disease / complications*
  • Crohn Disease / drug therapy
  • Female
  • Humans
  • Infliximab
  • Liver Neoplasms / chemically induced
  • Liver Neoplasms / etiology*
  • Lymphoma, T-Cell / chemically induced
  • Lymphoma, T-Cell / etiology*
  • Male
  • Splenic Neoplasms / chemically induced
  • Splenic Neoplasms / etiology*


  • Antibodies, Monoclonal
  • Infliximab